甲状腺乳头状癌伴桥本甲状腺炎患者BRAF^(V600E)基因突变与临床病理特征的关系  

Relationship between BRAF^(V600E) mutation and clinicopathological characteristics in patients with papillary thyroid carcinoma and Hashimoto's thyroiditis

作　　者：宰国真[1] 李维山 何晓燕[1] 孙海斌[1] ZAI Guo-zhen;LI Wei-shan;HE Xiao-yan;SUN Hai-bin(Department of Pathology,the Fifth Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,Henan,CHINA;Department of Pathology,Jiyuan Tumor Hospital,Jiyuan 454650,Henan,CHINA)

机构地区：[1]郑州大学第五附属医院病理科,河南郑州450052 [2]济源市肿瘤医院病理科,河南济源454650

出　　处：《海南医学》2021年第8期977-980,共4页Hainan Medical Journal

摘　　要：目的探讨BRAFV600E基因突变与甲状腺乳头状癌(PTC)伴桥本甲状腺炎(HT)患者临床病理特征的关联性。方法选取2017年5月至2020年8月郑州大学第五附属医院收治的PTC 162例伴HT及162例未伴HT患者,采用荧光PCR法比较两者BRAF^(V600E)基因突变情况,将PTC伴HT患者根据是否有BRAFV600E基因突变分为阳性组68例和阴性组94例,比较两组患者的一般资料,采用Spearman相关系数模型分析BRAFV600E基因突变与PTC伴HT患者临床病理特征的关联性。结果PTC伴HT患者BRAF^(V600E)基因突变阳性率为41.98%,明显低于未伴HT患者的70.99%,差异有统计学意义(P<0.05);PTC伴HT患者BRAFV600E突变阳性组患者的淋巴结转移、侵袭被膜占比分别为60.29%、13.24%,明显高于阴性组的15.96%、3.19%,差异均有统计学意义(P<0.05);PTC伴HT患者BRAFV600E突变与HT呈负相关(r=-0.516,P<0.05),与淋巴结转移、侵袭被膜呈正相关(r=0.619、0.577,P<0.05)。结论PTC伴HT者较不伴HT患者呈现出较低的BRAFV600E基因突变率和侵袭性,但突变阳性仍会增加肿瘤的侵袭性。Objective To investigate the relationship between BRAFV600Emutation and clinicopathological characteristics of patients with papillary thyroid carcinoma(PTC)and Hashimoto’s thyroiditis(HT).Methods From May2017 to August 2020,162 PTC patients with HT and 162 patients without HT who were admitted to the Fifth Affiliated Hospital of Zhengzhou University were selected in the study.The BRAF^(V600E) mutations were compared between the two groups by using fluorescent PCR.The PTC patients with HT were divided into a positive group of 68 cases and a negative group of 94 cases according to whether they have BRAF^(V600E)mutations.The general data of the patients were compared between the two groups,and the Spearman correlation coefficient model was used to analyze the association between BRAF^(V600E)mutation and the clinicopathological characteristics of PTC patients with HT.Results The positive rate of BRAF^(V600E)mutation was 41.98%in PTC patients with HT,which was significantly lower than 70.99%in PTC patients without HT,and the difference was statistically significant(P<0.05).The proportions of lymph node metastasis and invasion of the membrane were respectively 60.29%and 13.24%in PTC patients with HT and BRAF^(V600E)mutation positive group,which were significantly higher than corresponding 15.96%and 3.19%in the BRAF^(V600E) mutation negative group(both P<0.05).BRAF^(V600E)mutation in PTC patients with HT was negatively correlated with HT(r=-0.516,P<0.05),and positively correlated with lymph node metastasis and invasion of the envelope(r=0.619,0.577,P<0.05).Conclusion BRAF^(V600E)mutation rate and aggressiveness presents a lower rate in PTC patients with HT than without HT,but positive mutations will still increase tumor aggressiveness.

关 键 词：甲状腺乳头状癌 桥本甲状腺炎 BRAF^(V600E)基因突变 肿瘤T分期 淋巴结转移 侵袭被膜 相关性 

分 类 号：R736.1[医药卫生—肿瘤]